Advertisement

U.S. Markets closed

S&P Futures
6,003.75
0.00(0.00%)
Dow Futures
43,914.00
+4.00(+0.01%)
Nasdaq Futures
21,219.25
-5.50(-0.03%)
Russell 2000 Futures
2,398.30
+2.60(+0.11%)
Crude Oil
72.07
-0.29(-0.40%)
Gold
2,707.00
+1.20(+0.04%)

BridgeBio Pharma, Inc. (BBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

25.88

+0.27

(+1.05%)

At close: 04:00PM EST

26.03

+0.15

(+0.58%)

After hours:

07:29PM EST

Trade prices are not sourced from all markets

All

GlobeNewswire
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
- Case study co-authored by members of BridgeBio senior management and BridgeBio co-founder and MIT professor, Andrew W. Lo, Ph.D. - Case study features BridgeBio’s unique model that uses portfolio theory to enable early-stage research for genetic diseases and conditions that are not typically addressed by the pharmaceutical industry PALO ALTO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company f
Zacks
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.